Quest for the right Drug
רימודולין 5 מ"ג/מ"ל REMODULIN 5 MG/ML (TREPROSTINIL AS SODIUM)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תת-עורי, תוך-ורידי : S.C, I.V
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Posology : מינונים
2. DOSAGE AND ADMINISTRATION 2.1 General Remodulin can be administered without further dilution for subcutaneous administration, or diluted for intravenous infusion with Sterile Water for Injection or 0.9% Sodium Chloride Injection, prior to administration. 2.2 Initial Dose for Patients New to Prostacyclin Infusion Therapy Remodulin is indicated for subcutaneous (SC) or intravenous (IV) use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central intravenous line if the subcutaneous route is not tolerated because of severe site pain or reaction. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, reduce the infusion rate to 0.625 ng/kg/min. 2.3 Dosage Adjustments The goal of chronic dosage adjustments is to establish a dose at which PAH symptoms are improved, while minimizing excessive pharmacologic effects of Remodulin (headache, nausea, emesis, restlessness, anxiety and infusion site pain or reaction). The infusion rate should be increased in increments of 1.25 ng/kg/min per week for the first four weeks of treatment and then 2.5 ng/kg/min per week for the remaining duration of infusion, depending on clinical response. Dosage adjustments may be undertaken more often if tolerated. Avoid abrupt cessation of infusion [see Warnings and Precautions (5.2)]. Restarting a Remodulin infusion within a few hours after an interruption can be done using the same dose rate. Interruptions for longer periods may require the dose of Remodulin to be re-titrated. 2.4 Patients with Hepatic Insufficiency In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min ideal body weight. Remodulin has not been studied in patients with severe hepatic insufficiency [see Warnings and Precautions (5.3), Use In Specific Populations (8.6) and Clinical Pharmacology (12.3)]. 2.5 Administration Inspect parenteral drug products for particulate matter and discoloration prior to administration whenever solution and container permit. If either particulate matter or discoloration is noted, do not use. Subcutaneous Infusion Remodulin is administered subcutaneously by continuous infusion without further dilution, via a subcutaneous catheter, using an infusion pump designed for subcutaneous drug delivery. To avoid potential interruptions in drug delivery, the patient must have immediate access to a backup infusion pump and subcutaneous infusion sets. The ambulatory infusion pump used to administer Remodulin should: (1) be small and lightweight, (2) be adjustable to approximately 0.002 mL/hr, (3) have occlusion/no delivery, low battery, programming error and motor malfunction alarms, (4) have delivery accuracy of ±6% or better and (5) be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene or glass. Remodulin is administered subcutaneously by continuous infusion at a calculated Subcutaneous Infusion Rate (mL/hr) based on a patient's Dose (ng/kg/min), Weight (kg), and the Vial Strength (mg/mL) of Remodulin being used. During use, a single reservoir (syringe) of undiluted Remodulin can be administered up to 72 hours at 37°C. The Subcutaneous Infusion rate is calculated using the following formula: Subcutaneous Dose (ng/kg/min) x Weight (kg) x 0.00006* Infusion Rate = (mL/hr) Remodulin Vial Strength (mg/mL) *Conversion factor of 0.00006 = 60 min/hour x 0.000001 mg/ng Example calculations for Subcutaneous Infusion are as follows: Example 1: For a 60 kg person at the recommended initial dose of 1.25 ng/kg/min using the 1 mg/mL Remodulin, the infusion rate would be calculated as follows: Subcutaneous 1.25 ng/kg/min x 60 kg x 0.00006 Infusion Rate = = 0.005 mL/hr (mL/hr) 1 mg/mL Example 2: For a 65 kg person at a dose of 40 ng/kg/min using the 5 mg/mL Remodulin, the infusion rate would be calculated as follows: Subcutaneous 40 ng/kg/min x 65 kg x 0.00006 Infusion Rate = 5 mg/mL = 0.031 mL/hr (mL/hr) Intravenous Infusion External Intravenous Infusion Pump Remodulin must be diluted with either Sterile Water for Injection or 0.9% Sodium Chloride Injection and is administered intravenously by continuous infusion, via a surgically placed indwelling central venous catheter using an external infusion pump designed for intravenous drug delivery. If clinically necessary, a temporary peripheral intravenous cannula, preferably placed in a large vein, may be used for short term administration of Remodulin. Use of a peripheral intravenous infusion for more than a few hours may be associated with an increased risk of thrombophlebitis. To avoid potential interruptions in drug delivery, the patient must have immediate access to a backup infusion pump and infusion sets. The ambulatory infusion pump used to administer Remodulin should: (1) be small and lightweight, (2) have occlusion/no delivery, low battery, programming error and motor malfunction alarms, (3) have delivery accuracy of ±6% or better of the hourly dose, and (4) be positive pressure driven. The reservoir should be made of polyvinyl chloride, polypropylene or glass. Infusion sets with an in-line 0.22 or 0.2 micron pore size filter should be used. Diluted Remodulin has been shown to be stable at ambient temperature for up to 48 hours at concentrations as low as 0.004 mg/mL (4,000 ng/mL). Select the intravenous infusion rate to allow for a desired infusion period length of up to 48 hours between system changeovers. Typical intravenous infusion system reservoirs have volumes of 50 or 100 mL. With this selected Intravenous Infusion Rate (mL/hr) and the patient’s Dose (ng/kg/min) and Weight (kg), the Diluted Intravenous Remodulin Concentration (mg/mL) can be calculated using the following formula: Step 1 Diluted Dose Weight Intravenous x x 0.00006 (ng/kg/min) (kg) Remodulin = Concentration Intravenous Infusion Rate (mg/mL) (mL/hr) The Volume of Remodulin Injection needed to make the required Diluted Intravenous Remodulin Concentration for the given reservoir size can then be calculated using the following formula: Step 2 Diluted Intravenous Remodulin Total Volume of Diluted Volume of Concentration Remodulin Solution in Remodulin = (mg/mL) x Reservoir Injection Remodulin Vial (mL) (mL) Strength (mg/mL) The calculated volume of Remodulin Injection is then added to the reservoir along with the sufficient volume of diluent (Sterile Water for Injection or 0.9% Sodium Chloride Injection) to achieve the desired total volume in the reservoir. Example calculations for Intravenous Infusion are as follows: Example 3: For a 60 kg person at a dose of 5 ng/kg/min, with a predetermined intravenous infusion rate of 1 mL/hr and a reservoir of 50 mL, the Diluted Intravenous Remodulin Concentration would be calculated as follows: Step 1 Diluted = 0.018 Intravenous 5 ng/kg/min x 60 kg x 0.00006 mg/mL Remodulin = 1 mL/hr (18,000 Concentration ng/mL) (mg/mL) The Volume of Remodulin Injection (using 1 mg/mL Vial Strength) needed for a total Diluted Remodulin Concentration of 0.018 mg/mL and a total volume of 50 mL would be calculated as follows: Step 2 Amount of 0.018 mg/mL = x 50 mL = 0.9 mL Remodulin Injection 1 mg/mL (mL) The Diluted Intravenous Remodulin Concentration for the person in Example 3 would thus be prepared by adding 0.9 mL of 1 mg/mL Remodulin Injection to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 50 mL in the reservoir. The pump flow rate for this example would be set at 1 mL/hr. Example 4: For a 75 kg person at a dose of 30 ng/kg/min, with a predetermined intravenous infusion rate of 2 mL/hr, and a reservoir of 100 mL, the Diluted Intravenous Remodulin Concentration would be calculated as follows: Step 1 Diluted Intravenous 30 ng/kg/min x 75 kg x 0.00006 = 0.0675 mg/mL Remodulin = 2 mL/hr (67,500 ng/mL) Concentration (mg/mL) The Volume of Remodulin Injection (using 2.5 mg/mL Vial Strength) needed for a total Diluted Remodulin Concentration of 0.0675 mg/mL and a total volume of 100 mL would be calculated as follows: Step 2 Volume of 0.0675 mg/mL = x 100 mL = 2.7 mL Remodulin Injection 2.5 mg/mL (mL) The Diluted Intravenous Remodulin Concentration for the person in Example 4 would thus be prepared by adding 2.7 mL of 2.5 mg/mL Remodulin Injection to a suitable reservoir along with a sufficient volume of diluent to achieve a total volume of 100 mL in the reservoir. The pump flow rate for this example would be set at 2 mL/hr. 2.6 Patients Requiring Transition from Epoprostenol Transition from epoprostenol to Remodulin is accomplished by initiating the infusion of Remodulin and increasing it, while simultaneously reducing the dose of intravenous epoprostenol. The transition to Remodulin should take place in a hospital with constant observation of response (e.g., walk distance and signs and symptoms of disease progression). Initiate Remodulin at a recommended dose of 10% of the current epoprostenol dose, and then escalate as the epoprostenol dose is decreased (see Table 1 for recommended dose titrations). Patients are individually titrated to a dose that allows transition from epoprostenol therapy to Remodulin while balancing prostacyclin-limiting adverse events. Increases in the patient’s symptoms of PAH should be first treated with increases in the dose of Remodulin. Side effects normally associated with prostacyclin and prostacyclin analogs are to be first treated by decreasing the dose of epoprostenol. Table 1: Recommended Transition Dose Changes Step Epoprostenol Dose Remodulin Dose 1 Unchanged 10% Starting Epoprostenol Dose 80% Starting Epoprostenol 2 30% Starting Epoprostenol Dose Dose 60% Starting Epoprostenol 3 50% Starting Epoprostenol Dose Dose 40% Starting Epoprostenol 4 70% Starting Epoprostenol Dose Dose 20% Starting Epoprostenol 5 90% Starting Epoprostenol Dose Dose 5% Starting Epoprostenol 6 110% Starting Epoprostenol Dose Dose 110% Starting Epoprostenol Dose + additional 7 0 5-10% increments as needed 3. DOSAGE FORMS AND STRENGTHS 20-mL vial containing 50 mg treprostinil (2.5 mg per mL). 20-mL vial containing 100 mg treprostinil (5 mg per mL). 20-mL vial containing 200 mg treprostinil (10 mg per mL).
פרטי מסגרת הכללה בסל
א. התרופה האמורה תינתן לטיפול בחולה המוגדר ב-NYHA (New York Heart Association) כ-Class III ומעלה הסובל מיתר לחץ דם ריאתי עורקי. ב. התחלת הטיפול בתרופה האמורה תהיה על פי הוראתו של מנהל מחלקה בבית חולים שהוא רופא מומחה למחלות ריאה או רופא מומחה בקרדיולוגיה או רופא מומחה בטיפול נמרץ כללי או רופא מומחה בכירורגית כלי דם או רופא מומחה בקרדיולוגית ילדים או רופא מומחה במחלות ריאה ילדים או רופא מומחה בטיפול נמרץ ילדים או רופא מומחה בראומטולוגיה. ג. המשך הטיפול בתרופה האמורה ייעשה על פי מרשם של רופא מומחה למחלות ריאה או רופא מומחה בקרדיולוגיה או רופא מומחה בטיפול נמרץ כללי או רופא מומחה בכירורגית כלי דם או רופא מומחה בקרדיולוגית ילדים או רופא מומחה במחלות ריאה ילדים או רופא מומחה בטיפול נמרץ ילדים או רופא מומחה בראומטולוגיה. ד. ניתן להתחיל טיפול בתרופה האמורה במקרה בו התנגודת הריאתית המחושבת תישאר גבוהה אחרי טסט פרמקולוגי וזאת כאשר החולה סובל מ-NYHA Class III ומעלה ובעל מרחק הליכה ל-6 דקות הנמוך מ-400 מטרים ב-2 בדיקות עוקבות.ה. יש להימנע משילובי תרופות אלא לטפל בכל פעם בתרופה בודדת ורק עם כישלון בטיפול בה, לעבור לטיפול בתרופה אחרת, למעט המצבים הבאים: 1. בכישלון של טיפול ב-Sildenafil ניתן להוסיף במקרים נבחרים Iloprost באינהלציה או Bosentan או Ambrisentan או Macitentan.2. בכישלון של טיפול ב-Bosentan או Ambrisentan או Macitentan ניתן להוסיף במקרים נבחרים Iloprost באינהלציה או Sildenafil3. השילוב של Epoprostenol או Treprostinil עם Ambrisentan או Macitentan או Bosentan או Sildenafil יעשה רק לאחר כשלון של אחד מהפרוסטציקלינים האמורים כטיפול בודד.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/04/2004
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף